HK Stock Market Move | IMMUNEONCO-B(01541) rose nearly 4%. The self-developed subcutaneous formulation IMM0306S of Amuviraprop has received clinical trial approval.

IMMUNEONCO-B (01541) rose nearly 4%, reaching an increase of 2.98% at the time of writing, at 6.23 Hong Kong dollars, with a trading volume of 3.1192 million Hong Kong dollars. On the news front, according to the official WeChat account of Immuneonco, on December 18, the company announced that the Investigational New Drug (IND) application for their self-developed bispecific antibody-receptor recombinant protein drug, AMR-001 (subcutaneous injection) targeting CD47 and CD20 for the treatment of Systemic Lupus Erythematosus (SLE) has been formally accepted by the National Medical Products Administration (NMPA). This marks an important progress in the company's innovative drug development in the field of autoimmune diseases. AMR-001S is a subcutaneous formulation based on Immuneonco's core product AMR-001. AMR-001 (CD47xCD20, AMR-001) is the world's first CD47xCD20 dual target specific molecule that has entered into clinical stage, developed based on Immuneonco's "mAb-Trap" technology platform. Immuneonco has made comprehensive deployment of this product. It is worth mentioning that, at the 67th American Society of Hematology (ASH) annual meeting, Immuneonco announced the I/II phase clinical study data of AMR-001 (AMR-001) in combination with lenalidomide for the treatment of relapsed/refractory CD20-positive Follicular Lymphoma (R/R FL). The data showed that in patients who had previously failed at least one line of anti-CD20 monoclonal antibody treatment, the combination achieved an objective response rate (ORR) of 91.2% and a complete response rate (CR) of 67.6%. The safety profile was overall manageable with no risk of cytokine storms. This ongoing I/II phase study provides a promising new immunotherapy strategy for this currently incurable and limited treatment choice disease.